Japan's New CBD Import Rules: What Foreign Exporters Need to Know

Photo by taro ohtani via Unsplash.

Sometime in 2023, without much fanfare outside trade compliance circles, Japan tore up the rulebook that had defined legal CBD for over half a century and replaced it with something far more mathematically demanding. The old system asked one question: which part of the hemp plant did this come from? The new one asks a different question entirely: how many parts per million of THC does the finished product actually contain? That sounds like a technical footnote. It isn't. It's a complete reorientation of how Japan decides what counts as legal hemp-derived product, and it has real consequences for who can sell into one of Asia's most lucrative but historically closed CBD markets.

For years, the rule was blunt and unforgiving: legal extraction was limited to mature hemp stalks and seeds, full stop. It didn't matter if a company's flower-derived extract tested at zero THC in a certified lab in Colorado or Ljubljana -- if it came from leaves or flowers rather than stalks and seeds, it was contraband in Japan. That single restriction quietly locked out a huge swath of the international CBD industry and, notably, discouraged Japan's own major trading houses from touching the category at all. The 2023 revision to the Cannabis Control Act finally opened the door to whole-plant extraction. But anyone who read that as a simple loosening of restrictions missed the fine print. What Japan built instead is a tiered structure of THC thresholds that vary by product category, and threading that needle now requires a level of technical and laboratory rigor that many established exporters aren't set up for.

From Plant-Part Bans to a THC Standard

Photo by 1CzPhoto via Pixabay.

To understand why this shift matters, it helps to know how narrow the old rule actually was. Japan's Cannabis Control Act, in place in largely the same form since the postwar occupation era, drew its legal line at plant anatomy rather than chemistry. Extraction from mature stalks and seeds was permitted; extraction from leaves and flowers was not, regardless of how much or how little THC ended up in the final product. A CBD isolate pulled from hemp flower and tested at non-detectable THC levels was still, on paper, treated the same as raw cannabis flower -- illegal to import, sell, or possess.

That plant-part restriction did real economic damage to the market before it was ever repealed. Industry accounts from the period describe U.S. manufacturers who simply skipped Japan rather than retool their entire supply chain around stalk-and-seed-only extraction, since most commercial CBD production worldwide runs through flower and biomass, not stalks. It also kept Japan's large sogo shosha trading conglomerates -- companies with the logistics and capital to move any product category at scale -- on the sidelines of CBD entirely, wary of a legal gray zone with criminal liability attached.

The 2023 revision, which now operates alongside the existing Narcotics and Psychotropics Control Act, threw out the plant-part distinction altogether. Under the current framework, CBD extracted from any part of the plant -- leaves, flowers, stalks, seeds -- is permitted, provided the final THC content stays under 1 ppm as a general ceiling. That's not a minor tolerance adjustment or a bureaucratic tidy-up. It's a structural redefinition of what Japan considers legal hemp product, moving the entire regulatory logic from botany to chemistry. The catch, as exporters are now discovering, is that 1 ppm isn't actually the only number that matters.

The New THC Thresholds, Category by Category

Japan's allowable THC limits vary sharply by CBD product type, ranging from 10 ppm for oils down to just 0.1 ppm for water-based products, with other products capped at 1 ppm.

Japan's new framework doesn't apply one THC ceiling across the board -- it applies different ceilings depending on what category of product you're shipping, and the differences between those categories carry real weight. Oils are permitted up to 10 ppm THC. Water-based products, by contrast, must stay under 0.10 ppm -- a hundred-fold stricter standard. Everything else falls under a general 1 ppm cap. On paper that looks like a workable tiered system. In practice, the Ministry of Health, Labour and Welfare's Narcotics Control Division has spent considerable time since the revision clarifying what actually qualifies as an oil versus falling into that stricter general category, because the industry kept getting it wrong.

The complication comes down to concentration, not just format. Dr. Yuji Masataka, recognized as Japan's first medical cannabis specialist, has flagged a rule requiring products classified as oils to contain at least 90% of the relevant compounds by volume to actually qualify for the 10 ppm allowance. Push cannabinoid concentration above roughly 10% of the formulation, and the product risks falling out of the oil category and into the far stricter 1 ppm bracket. That threshold sounds generous until you compare it against what's actually sold internationally. Most CBD oils on shelves in the U.S. and Europe run somewhere between 5% and 40% cannabinoid concentration -- meaning a large share of standard commercial formulations sit right at or above the line where Japan's classification flips against them.

The practical fallout is that products marketed and labeled identically everywhere else in the world may not be legally equivalent once they hit Japanese customs. A full-spectrum tincture bottled at 20% concentration for the American market could clear customs in Los Angeles without issue and then get reclassified out of the oil category entirely in Tokyo, subjecting it to the tighter 1 ppm THC standard instead of the 10 ppm allowance it was formulated to. Bulk suppliers face an even blunter problem: concentrated crude oil, the raw material much of the finished-goods industry is built on, may not meet the definition of an oil under this framework at all, leaving ingredient exporters with a product that doesn't cleanly fit any category Japan has actually defined.

What Exporters Now Have to Prove at the Border

Photo by www.kaboompics.com via Pexels.

Getting product past Japanese customs now runs through a formal licensing gate before a single shipment moves. Companies must first secure permission from MHLW's Department of Drug Control, a step that applies regardless of how established the brand is elsewhere. That said, the paperwork burden inside that process has actually shifted in exporters' favor in one respect: the old requirement to submit extensive extraction documentation and photographic evidence of processing methods has been dropped, which is a genuine reduction in administrative friction compared to the previous regime.

What's replaced it is more demanding in a different way. Every shipment now requires a Certificate of Analysis from a laboratory accredited to ISO 17025 standards, confirming the product's THC content complies with whichever category threshold applies. This isn't optional paperwork filed once and forgotten -- it's a mandatory, shipment-level requirement, and the accreditation standard matters. ISO 17025 is a specific, internationally recognized benchmark for testing and calibration lab competence, and Japanese regulators are treating it as the floor for what counts as a credible result.

Licensing doesn't stop at the border either. It extends backward through the supply chain to cultivation and processing, meaning companies need documented records and lab testing in place well before goods are ever presented to customs -- not scrambled together after a shipment gets flagged. That backward-reaching scrutiny reflects a broader problem Japanese regulators are clearly aware of: the international CBD industry has a documented history of certifications that don't hold up, including lab reports that were inaccurate, outdated, or in some cases fabricated outright. Rather than take a foreign lab's THC-free claim at face value, Japan's system is built around verifying it independently, which means exporters relying on questionable or unaccredited testing partners are likely to find their compliance history under real examination rather than a rubber stamp.

Established Brands Face a Compliance Gap

Photo by cottonbro studio via Pexels.

The gap between Japan's new rules and existing product lines isn't theoretical -- it shows up directly in the catalogs of some of the CBD industry's best-known international names. Industry analysis has flagged suppliers including PharmaHemp out of Slovenia, American brands Elixinol and CBDfx, Denmark's Endoca, and the UK's Naturecan as companies whose product formulations don't map cleanly onto Japan's category-specific ppm system. These aren't fringe operators; they're established players with distribution across North America, Europe, and beyond, built on THC allowances that made sense in their home markets and simply don't translate.

The core issue is that THC-free framing means something different depending on jurisdiction. A tincture legally marketed as THC-free in the EU, where the standard has historically hovered around 0.2-0.3% THC by dry weight for the plant material itself, or in the U.S. under the 0.3% Farm Bill threshold, can still fail Japan's oil-category test outright. If that product's cannabinoid concentration is high enough to push it past the 90% oil-classification threshold Dr. Masataka has warned about, it lands in the stricter 1 ppm bracket regardless of what its home-market label claims.

For companies used to selling into dozens of markets off a single production run, that mismatch means real cost. Entering Japan properly requires new extraction batches formulated specifically to hit Japan's ppm math, fresh ISO 17025 lab testing to back it up, and new Certificates of Analysis tied to those specific batches -- not a repurposed COA from a European or American test run. That's added lead time and added expense layered onto a market entry that used to be blocked outright and is now merely expensive to do correctly. Larger suppliers with dedicated compliance teams and the capital to run a Japan-specific product line can absorb that. Smaller exporters, the kind operating without in-house regulatory staff, are the ones most likely to either get turned away at customs or decide the juice isn't worth the squeeze.

The CBN Ban Signals a Narrower Path Ahead

Photo by Duong Nguyen via Unsplash.

Just as the CBD market was adjusting to its new opening, Japan moved in the opposite direction on a related cannabinoid. Starting June 1, 2026, Japan is banning the possession, use, import, sale, and manufacture of CBN products outright -- and notably, that ban applies even to products consumers already purchased legally while overseas, with no grandfather exemption for goods bought before the rule took effect. Japan's Ministry of Health confirmed the ban in March 2026, giving businesses and industry groups only a few months to clear existing inventory before the restriction hit.

The market impact isn't trivial. Industry groups had estimated Japan's CBN product market at roughly ¥10 billion annually before the ban was announced, meaning a meaningful commercial category is being wound down on short notice rather than phased out gradually. It's worth being precise about scope here: THC-free CBD itself is untouched by this rule and remains legal under the framework described above. The CBN ban is a separate action targeting a specific cannabinoid, not a reversal of the broader CBD liberalization.

But the speed and selectivity of the CBN action is the real signal for exporters to pay attention to. Japan has shown, within the same regulatory window as its CBD reform, that it's willing to move quickly and narrowly against individual cannabinoids when it decides the risk profile warrants it -- with minimal transition time and no exemption for inventory purchased in good faith elsewhere. That's a useful data point for any company treating Japan's current CBD rules as a fixed target rather than a live one. The framework that governs oils, water-based products, and general THC ceilings today is the product of a 2023 revision that's already barely two years old at the time of the CBN action; there's no reason to assume it's finished evolving.

Give Japan credit for what it actually did: the shift from a plant-part rule to a THC-content standard is a genuine widening of the door for whole-plant CBD extraction, ending a restriction that had kept much of the global industry out for decades. That's not a cosmetic change, and companies that dismiss it as such are missing a real opportunity. But the category-specific ppm math built into the new system means that clearing customs in Rotterdam, Los Angeles, or Ljubljana proves nothing about clearing customs in Tokyo. Those are separate tests with separate numbers, and a product's THC-free status at home carries no weight against Japan's oil-classification threshold or its stricter water-based ceiling.

The exporters likely to actually capture share in this market are the ones treating Japan as its own formulation project rather than an afterthought -- building relationships with ISO 17025-accredited labs early, running Japan-specific production batches, and pricing that extra step into their market-entry cost rather than discovering it after a shipment gets held at the border. Competitors still shipping generic THC-free stock and hoping it happens to test under the right threshold are going to lose product, time, and money finding out the hard way.

The CBN ban is the part of this story that should stick with anyone making sourcing decisions right now. A market worth an estimated ¥10 billion a year got wound down with a few months' notice and no exemption for goods already purchased legally abroad. That's not a reason to avoid Japan -- it's a reason to verify current MHLW guidance before every shipment rather than working off last year's compliance memo, however solid that memo seemed at the time.